| BI 1356 |
| 8-[(3R)-3-aminopiperidin-1-yl]-7-(but-2-yn-1-yl)-3- methyl-1-[(4-methylquinazolin-2-yl)methyl]-3,7-dihydro-1H-purine-2,6-dione |
| (CAS 668270-12-0) |
 |
| Description： |
Linagliptin (BI-1356, trade names Tradjenta (US), Trajenta (worldwide)) is a DPP-4 inhibitor developed by Boehringer Ingelheim for treatment of type II diabetes.
Linagliptin (once-daily) was approved by the U.S. Food and Drug Administration (FDA) on 2 May 2011 for treatment of type II diabetes.[1] It is being marketed by Boehringer Ingelheim and Lilly.
|
| Product No. |
KT00169 |
| Product Name |
BI 1356 |
| Synonyms |
Tradjenta,Linagliptin |
| Formal Name |
8-[(3R)-3-aminopiperidin-1-yl]-7-(but-2-yn-1-yl)-3- methyl-1-[(4-methylquinazolin-2-yl)methyl]-3,7-dihydro-1H-purine-2,6-dione |
| CAS Number |
668270-12-0 |
| Molecular Formula |
C25H28N8O2 |
| Formula Weight |
472.54 |
| Formulation |
A crystalline solid |
| Purity |
98%min |
| Stability |
2 years |
| Storage |
-20°C |
| Shipping |
USD45 for Europe and USA. No shipping charge once amount reach USD500 |
| Quality Control |
HNMR,CNMR,LCMS,HPLC,IR,etc. |
| Price & Availability |
In Stock. Price Negotiated. |
|
| Related Products： |
Alogliptin
Alogliptin Benzoate
Saxagliptin
Saxagliptin hydrate
Sitagliptin
itagliptin phosphate
Teneligliptin
Teneligliptin hydrobromide
Trelagliptin
Trelagliptin succinate
|
|
